112 related articles for article (PubMed ID: 36017597)
1. Update on the omicron sub-variants BA.4 and BA.5.
Tallei TE; Alhumaid S; AlMusa Z; Fatimawali ; Kusumawaty D; Alynbiawi A; Alshukairi AN; Rabaan AA
Rev Med Virol; 2023 Jan; 33(1):e2391. PubMed ID: 36017597
[TBL] [Abstract][Full Text] [Related]
2. Omicron Sub-Lineages (BA.1.1.529 + BA.*) Current Status in Ecuador.
Carrazco-Montalvo A; Herrera-Yela A; Alarcón-Vallejo D; Gutiérrez-Pallo D; Armendáriz-Castillo I; Andrade-Molina D; Muñoz-Mawyin K; Fernández-Cadena JC; Morey-León G; Usfq-Covid-Consortium ; Crn Influenza Y Ovr-Inspi ; Patiño L
Viruses; 2022 May; 14(6):. PubMed ID: 35746651
[TBL] [Abstract][Full Text] [Related]
3. Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England.
Strasser ZH; Greifer N; Hadavand A; Murphy SN; Estiri H
JAMA Netw Open; 2022 Oct; 5(10):e2238354. PubMed ID: 36282501
[TBL] [Abstract][Full Text] [Related]
4. Global Distribution, Dispersal Patterns, and Trend of Several Omicron Subvariants of SARS-CoV-2 across the Globe.
Kopsidas I; Karagiannidou S; Kostaki EG; Kousi D; Douka E; Sfikakis PP; Moustakidis S; Kokkotis C; Tsaopoulos D; Tseti I; Zaoutis T; Paraskevis D
Trop Med Infect Dis; 2022 Nov; 7(11):. PubMed ID: 36422924
[TBL] [Abstract][Full Text] [Related]
5. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
[TBL] [Abstract][Full Text] [Related]
6. Mapping the Early Dispersal Patterns of SARS-CoV-2 Omicron BA.4 and BA.5 Subvariants in the Absence of Travel Restrictions and Testing at the Borders in Europe.
Kostaki EG; Mossialos E; Tseti I; Sfikakis PP; Paraskevis D
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680171
[TBL] [Abstract][Full Text] [Related]
7. The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages.
Xiang T; Wang J; Zheng X
Virol Sin; 2022 Dec; 37(6):786-795. PubMed ID: 36427646
[TBL] [Abstract][Full Text] [Related]
8. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.
Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ
Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.
He X; Su J; Ma Y; Zhang W; Tang S
Front Immunol; 2022; 13():945930. PubMed ID: 36090988
[TBL] [Abstract][Full Text] [Related]
10. Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark.
Lyngse FP; Kirkeby CT; Denwood M; Christiansen LE; Mølbak K; Møller CH; Skov RL; Krause TG; Rasmussen M; Sieber RN; Johannesen TB; Lillebaek T; Fonager J; Fomsgaard A; Møller FT; Stegger M; Overvad M; Spiess K; Mortensen LH
Nat Commun; 2022 Sep; 13(1):5760. PubMed ID: 36180438
[TBL] [Abstract][Full Text] [Related]
11. Delineating the Spread and Prevalence of SARS-CoV-2 Omicron Sublineages (BA.1-BA.5) and Deltacron Using Wastewater in the Western Cape, South Africa.
Johnson R; Mangwana N; Sharma JR; Muller CJF; Malemela K; Mashau F; Dias S; Ramharack P; Kinnear C; Glanzmann B; Viraragavan A; Louw J; Surujlal-Naicker S; Nkambule S; Webster C; Mdhluli M; Gray G; Mathee A; Preiser W; Vorster A; Dalvie S; Street R
J Infect Dis; 2022 Oct; 226(8):1418-1427. PubMed ID: 36017801
[TBL] [Abstract][Full Text] [Related]
12. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
[TBL] [Abstract][Full Text] [Related]
13. Worldwide vaccine inequality threatens to unleash the next COVID-19 variant.
Oehler RL; Vega VR
Int J Infect Dis; 2022 Oct; 123():133-135. PubMed ID: 35988865
[TBL] [Abstract][Full Text] [Related]
14. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
[TBL] [Abstract][Full Text] [Related]
15. Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections.
Andeweg SP; de Gier B; Eggink D; van den Ende C; van Maarseveen N; Ali L; Vlaemynck B; Schepers R; Hahné SJM; Reusken CBEM; de Melker HE; van den Hof S; Knol MJ
Nat Commun; 2022 Aug; 13(1):4738. PubMed ID: 35961956
[TBL] [Abstract][Full Text] [Related]
16. Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events.
Ou J; Lan W; Wu X; Zhao T; Duan B; Yang P; Ren Y; Quan L; Zhao W; Seto D; Chodosh J; Luo Z; Wu J; Zhang Q
Signal Transduct Target Ther; 2022 Apr; 7(1):138. PubMed ID: 35474215
[TBL] [Abstract][Full Text] [Related]
17. Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa.
Wolter N; Jassat W; Walaza S; Welch R; Moultrie H; Groome MJ; Amoako DG; Everatt J; Bhiman JN; Scheepers C; Tebeila N; Chiwandire N; du Plessis M; Govender N; Ismail A; Glass A; Mlisana K; Stevens W; Treurnicht FK; Subramoney K; Makatini Z; Hsiao NY; Parboosing R; Wadula J; Hussey H; Davies MA; Boulle A; von Gottberg A; Cohen C
Nat Commun; 2022 Oct; 13(1):5860. PubMed ID: 36195617
[TBL] [Abstract][Full Text] [Related]
18. The neutralizing response to SARS-CoV-2 Omicron variants BA.1 and BA.2 in COVID-19 patients and homologous and heterologous vaccinees.
Dapporto F; Leonardi M; Trombetta CM; Semplici C; Piu P; Piccini G; Benincasa L; Marchi S; Andreano E; Lovreglio P; Buonvino N; Decaro N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Rappuoli R; Molesti E; Manenti A; Montomoli E
Hum Vaccin Immunother; 2022 Nov; 18(6):2129196. PubMed ID: 36269939
[TBL] [Abstract][Full Text] [Related]
19. Omicron subvariant BA.5 is highly contagious but containable: Successful experience from Macau.
Xu C; Wang J; Yu L; Sui X; Wu Q
Front Public Health; 2022; 10():1029171. PubMed ID: 36703829
[TBL] [Abstract][Full Text] [Related]
20. The Omicron Variant BA.1.1 Presents a Lower Pathogenicity than B.1 D614G and Delta Variants in a Feline Model of SARS-CoV-2 Infection.
Martins M; do Nascimento GM; Nooruzzaman M; Yuan F; Chen C; Caserta LC; Miller AD; Whittaker GR; Fang Y; Diel DG
J Virol; 2022 Sep; 96(17):e0096122. PubMed ID: 36000850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
